In Vitro Structure–Activity Relationship Stability Study of Antisense Oligonucleotide Therapeutics Using Biological Matrices and Nucleases
Pharmacology Research & Perspectives · 2025-06 · 13 (3)
DOI: 10.1002/prp2.70096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 16.04.2025. Verfasst von Jelena Lovrić und 7 weiteren Autor:innen. Beteiligte Einrichtung: DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Phosphodiesterase I. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The primary degradation pathway for antisense oligonucleotides (ASOs) involves endonuclease and exonuclease‐mediated breakdown. The effect of various chemical modifications on the stability of oligonucleotides has not been systematically investigated. The aim of this study was to develop in vitro assays to predict in vivo metabolism of ASOs. Stability studies of ASOs with varying phosphorothioate/phosphodiester (PS/PO) content were conducted using nucleolytic matrices (snake venom 3′‐exonuclease phosphodiesterase I [PDEI], mouse serum, and mouse liver homogenate) and analyzed by gel electrophoresis and liquid chromatography with ultraviolet and mass spectrometry detection (LC‐UV/MS). Both sequence composition and backbone chemistry play important roles in influencing the stability of ASOs. Nucleolytic sensitivity observed with PDEI and mouse serum shows that ASOs with one PO modification in the backbone have higher stability than ASOs having two or three PO links, and with a lower PO content, the sequence has a larger influence on stability. Furthermore, the impact of a 5‐methylcytidine nucleoside ( Me C) on stability was observed. When the PO link was located after Me C (from 3′ end), resistance toward nuclease hydrolysis increased, while the PO modification being before Me C had no protective effect. Employing nucleases and comparing stability data with matrices of animal origin holds promise for a future fast‐track assessment of drug stability, enabling the efficient selection of optimal drug candidates for subsequent in vivo studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Cell, Gene and RNA Therapeutics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
ORCID-Profile: XueQing Li, Deepak Kumar Bhatt
Zitieren
APA
Lovrić, J., Yan, J., Li, X., Karlsborn, T., Bood, M., Dahlén, A., Hilgendorf, C., & Bhatt, D. K. (2025). In Vitro Structure–Activity Relationship Stability Study of Antisense Oligonucleotide Therapeutics Using Biological Matrices and Nucleases. Pharmacology Research & Perspectives, 13(3). https://doi.org/10.1002/prp2.70096
Vancouver
Lovrić J, Yan J, Li X, Karlsborn T, Bood M, Dahlén A, et al. In Vitro Structure–Activity Relationship Stability Study of Antisense Oligonucleotide Therapeutics Using Biological Matrices and Nucleases. Pharmacology Research & Perspectives. 2025;13(3). doi:10.1002/prp2.70096
BibTeX
@article{Lovri2025,
author = {Lovrić, Jelena and Yan, Jingjing and Li, XueQing and Karlsborn, Tony and Bood, Mattias and Dahlén, Anders and Hilgendorf, Constanze and Bhatt, Deepak Kumar},
title = {In Vitro Structure–Activity Relationship Stability Study of Antisense Oligonucleotide Therapeutics Using Biological Matrices and Nucleases},
journal = {Pharmacology Research & Perspectives},
year = {2025},
volume = {13},
number = {3},
doi = {10.1002/prp2.70096}
}
EUVIMED